PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q4 2017 13F Holders as of 31 Dec 2017

Type / Class
Equity / COM
Total 13F shares
61,010,786
Share change
-2,098,014
Total reported value
$362,979,514
Put/Call ratio
157%
Price per share
$5.95
Number of holders
149
Value change
-$13,457,081
Number of buys
70
Number of sells
57

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q4 2017

As of 31 Dec 2017, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 149 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 61,010,786 shares. The largest 10 holders included FEDERATED INVESTORS INC /PA/, BlackRock Inc., EAGLE ASSET MANAGEMENT INC, Vanguard Group Inc, CARILLON TOWER ADVISERS, INC., STATE STREET CORP, BAKER BROS. ADVISORS LP, PINNACLE ASSOCIATES LTD, FMR LLC, and ARDSLEY ADVISORY PARTNERS. This page lists 149 institutional shareholders reporting positions in this security for the Q4 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.